HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMO sued over contact lens solution

This article was originally published in The Tan Sheet

Executive Summary

Californian Maria Ruiz alleges in a complaint Dec. 22 that Advanced Medical Optics falsely advertised Complete Easy Rub Multi-Purpose Solutionfor contact lens care as a "new" formulation with "enhanced protection" against Acanthamoeba keratitis infections. The complaint, filed in California State Superior Court in Orange County, alleges the Easy Rub formula launched in 2007 is identical to an old formula AMO used in a private-label product, law firm Lieff Cabraser Heimann & Bernstein, counsel for the plaintiff, says in a release. The Easy Rub marketing provides "a false sense of security" since the solution's disinfectant ingredient "is not effective against Acanthamoeba organisms," the law firm adds. Santa Ana, Calif.-based AMO recalled a "no rub" solution in May 2007 after users experienced Acanthamoeba-related eye infections (1"The Tan Sheet" June 23, 2008, p. 12)

You may also be interested in...



Contact Lens Care Solutions Should Require “Rubbing” – FDA Panel

All multipurpose contact lens care solutions should include directions for "rubbing" as well as rinsing to help avoid potential eye infections, including solutions previously approved with "no rub" labels on exterior packaging, FDA's Ophthalmic Devices Panel says

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

UsernamePublicRestriction

Register

RS136364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel